4-hydroxycinnamate lowers plasma and hepatic lipids without changing antioxidant enzyme activities.
OBJECTIVE
The purpose of this study was to investigate the influence of 4-hydroxycinnamate (4-(OH)-C) supplement on the lipid metabolism and antioxidant system of rats fed a high-cholesterol diet.


METHODS
Three groups of rats were given a diet containing 1 g cholesterol/kg for 6 weeks. The control group only received a high cholesterol diet, whereas the other two groups received a diet including lovastatin or 4-(OH)-C (0.1 g/100 g).


RESULTS
The plasma total cholesterol concentration was significantly lowered by the 4-(OH)-C supplement, whereas the HDL-cholesterol level was higher in this group. The 4-(OH)-C supplement significantly lowered the hepatic cholesterol and triglycerides levels, respectively. Accumulation of hepatic lipid droplet was the highest in control group; however, it was decreased by supplementation of the 4-(OH)-C and the lovastatin. The hepatic HMG-CoA reductase activities were not significantly different between the groups, whereas the ACAT activity was significantly lowered in the lovastatin group. The 4-(OH)-C significantly lowered the hepatic TBARS content. And it did not alter the neutral sterol and total fecal sterol, however, the fecal acidic sterol was higher in the lovastatin and the 4-(OH)-C groups than in the control group.


CONCLUSIONS
These results indicate that 4-(OH)-C was effective in lowering the plasma cholesterol and hepatic lipids.
Department of Food Science and Nutrition, Kyungpook National University, Taegu, Korea.
Jeong-Sun
JS
Lee
Song-Hae
SH
Bok
Yong Bok
YB
Park
Mi-Kyung
MK
Lee
Myung-Sook
MS
Choi
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D002791:Cholesterol, Dietary / Q000494:pharmacology; D003373:Coumaric Acids / Q000097:blood / Q000494:pharmacology*; D004435:Eating / Q000187:drug effects; D004798:Enzymes / Q000187:drug effects; D005243:Feces / Q000737:chemistry; D006903:Hydroxymethylglutaryl CoA Reductases / Q000187:drug effects / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000378:metabolism*; D008148:Lovastatin / Q000494:pharmacology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011422:Propionates; D051381:Rats; D017207:Rats, Sprague-Dawley; D002785:Sterol O-Acyltransferase / Q000187:drug effects / Q000378:metabolism; D013261:Sterols / Q000032:analysis; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D000924:Anticholesteremic Agents; D000975:Antioxidants; D002791:Cholesterol, Dietary; D003373:Coumaric Acids; D004798:Enzymes; D000960:Hypolipidemic Agents; D008055:Lipids; D011422:Propionates; D013261:Sterols; D017392:Thiobarbituric Acid Reactive Substances; D008148:Lovastatin; D006903:Hydroxymethylglutaryl CoA Reductases; D002785:Sterol O-Acyltransferase; C495469:p-coumaric acid